Article(id=1325221194428973581, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1325221086685704257, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2026.08.017, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1773158400000, receivedDateStr=2026-03-11, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1793886954170, onlineDateStr=2026-11-05, pubDate=1786291200000, pubDateStr=2026-08-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1793886954170, onlineIssueDateStr=2026-11-05, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1793886954170, creator=13701087609, updateTime=1793886954170, updator=13701087609, issue=Issue{id=1325221086685704257, tenantId=1146029695717560320, journalId=1319690329412173987, year='2026', volume='47', issue='8', pageStart='831', pageEnd='950', issueExtLink='null', onlineDate='null', pubDate='1786291200000', pubDateStr='2026-08-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=1, specialIssue=null, createTime=1793886928482, creator='13701087609', updateTime=1793934727548, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1325421571296330250, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1325221086685704257, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1325421571296330251, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1325221086685704257, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=946, endPage=950, ext={EN=ArticleExt(id=1325221194659660303, articleId=1325221194428973581, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Clinical research progress of the anti-infective drug oritavancin, columnId=1325221194584162830, journalTitle=World Clinical Drug, columnName=Review, runingTitle=null, highlight=null, articleAbstract=

Oritavancin is a novel antimicrobial agents with broad-spectrum antibacterial activity against multi-drug resistant bacteria, particularly showing excellent activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant strains. Oritavancin is mainly used to treat acute bacterial skin and skin structure infections caused by Gram-positive bacteria and offers the advantage of convenient administration. This article mainly reviewed the clinical studies and related aspects of oritavancin, in order to provide reference for its clinical application.

, authors=Qiang LU, Wen TANG, Hui LI, Dong YI, Jun TAN*, authorsList=Qiang LU, Wen TANG, Hui LI, Dong YI, Jun TAN, authorCompany=null, correspAuthors=Jun TAN, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1325221194953261585, articleId=1325221194428973581, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=抗感染药物奥利万星的临床研究进展, columnId=1325221194743546384, journalTitle=世界临床药物, columnName=综述评论, runingTitle=null, highlight=null, articleAbstract=

奥利万星是一种新型糖肽类抗菌药物,对多重耐药菌具有广谱抗菌活性,特别对耐甲氧西林金黄色葡萄球菌和万古霉素耐药菌株具有极佳的抗菌活性。奥利万星主要用于治疗革兰氏阳性菌引起的急性细菌性皮肤及皮肤结构感染,具有给药便携性优势。该文主要对奥利万星的临床研究作综述,以期为其临床应用提供参考。

, authors=卢强, 汤文, 李会, 奕栋, 谭俊*, authorsList=卢强, 汤文, 李会, 奕栋, 谭俊, authorCompany=null, correspAuthors=谭俊, authorNote=

卢强,硕士研究生,研究方向:微生物药物。

, correspAuthorsNote=
谭俊,副研究员,研究方向:微生物药物。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=gM9l08YqXP/Xoh9CY4PuWg==, magXml=g01PLrjyma0yb9Aw2ABolg==, pdfUrl=null, pdf=xI4nvbpBcMxf9mrz/As35A==, pdfFileSize=1003576, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=CTwrielNribMvvp8w9i9Ag==, mapNumber=null, fund=null)}, authors=[Author(id=1325221198086406678, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1325221198182875672, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, authorId=1325221198086406678, language=EN, stringName=Qiang LU, firstName=Qiang, middleName=null, lastName=LU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=China State Institute of Pharmaceutical Industry, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1325221198568751641, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, authorId=1325221198086406678, language=CN, stringName=卢强, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院,上海 201203, bio={"content":"

卢强,硕士研究生,研究方向:微生物药物。

"}, bioImg=null, bioContent=

卢强,硕士研究生,研究方向:微生物药物。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1325221197658587666, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, xref=null, ext=[AuthorCompanyExt(id=1325221197683753491, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, companyId=1325221197658587666, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1325221197704725012, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, companyId=1325221197658587666, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海 201203)])]), Author(id=1325221198925267483, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1325221199034319389, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, authorId=1325221198925267483, language=EN, stringName=Wen TANG, firstName=Wen, middleName=null, lastName=TANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=China State Institute of Pharmaceutical Industry, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1325221199340503582, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, authorId=1325221198925267483, language=CN, stringName=汤文, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1325221197658587666, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, xref=null, ext=[AuthorCompanyExt(id=1325221197683753491, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, companyId=1325221197658587666, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1325221197704725012, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, companyId=1325221197658587666, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海 201203)])]), Author(id=1325221199407612448, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1325221201076945442, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, authorId=1325221199407612448, language=EN, stringName=Hui LI, firstName=Hui, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=China State Institute of Pharmaceutical Industry, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1325221201160831523, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, authorId=1325221199407612448, language=CN, stringName=李会, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1325221197658587666, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, xref=null, ext=[AuthorCompanyExt(id=1325221197683753491, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, companyId=1325221197658587666, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1325221197704725012, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, companyId=1325221197658587666, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海 201203)])]), Author(id=1325221201215357477, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1325221201521541671, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, authorId=1325221201215357477, language=EN, stringName=Dong YI, firstName=Dong, middleName=null, lastName=YI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=China State Institute of Pharmaceutical Industry, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1325221201588650536, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, authorId=1325221201215357477, language=CN, stringName=奕栋, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1325221197658587666, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, xref=null, ext=[AuthorCompanyExt(id=1325221197683753491, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, companyId=1325221197658587666, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1325221197704725012, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, companyId=1325221197658587666, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海 201203)])]), Author(id=1325221201848697386, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1325221201928389164, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, authorId=1325221201848697386, language=EN, stringName=Jun TAN, firstName=Jun, middleName=null, lastName=TAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=China State Institute of Pharmaceutical Industry, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1325221202003886637, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, authorId=1325221201848697386, language=CN, stringName=谭俊, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=中国医药工业研究总院,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1325221197658587666, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, xref=null, ext=[AuthorCompanyExt(id=1325221197683753491, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, companyId=1325221197658587666, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1325221197704725012, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, companyId=1325221197658587666, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海 201203)])])], keywords=[Keyword(id=1325221202091967022, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, language=EN, orderNo=1, keyword=oritavancin), Keyword(id=1325221202276516399, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, language=EN, orderNo=2, keyword=methicillin-resistant Staphylococcus aureus), Keyword(id=1325221202385568304, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, language=EN, orderNo=3, keyword=acute bacterial skin and skin structure infections), Keyword(id=1325221202444288561, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, language=CN, orderNo=1, keyword=奥利万星), Keyword(id=1325221202498814514, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, language=CN, orderNo=2, keyword=耐甲氧西林金黄色葡萄球菌), Keyword(id=1325221202565923379, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, language=CN, orderNo=3, keyword=急性细菌性皮肤及皮肤结构感染)], refs=[Reference(id=1325221202939216437, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Turner N A, Sharma-Kuinkel B K, Maskarinec S A, et al.Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research[J]. Nat Rev Microbiol, 2019,17(4): 203-218., articleTitle=null, refAbstract=null), Reference(id=1325221203115377206, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Galfo V, Tiseo G, Riccardi N, et al. Therapeutic drug monitoring of antibiotics for methicillin-resistant Staphylococcus aureus infections: an updated narrative review for clinicians[J]. Clin Microbiol Infect, 2025, 31(2):194-200., articleTitle=null, refAbstract=null), Reference(id=1325221203186680375, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=刘珊, 樊钱永. 沈舜义. 抗生素临床研究新进展[J]. 世界临床药物, 2017, 38(3): 200-203., articleTitle=null, refAbstract=null), Reference(id=1325221203253789240, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Jean S S, Liu I M, Hsieh P C, et al. Off-label use versus formal recommendations of conventional and novel antibiotics for the treatment of infections caused by multidrug-resistant bacteria[J]. Int J Antimicrob Agents, 2023, 61(5): 106763., articleTitle=null, refAbstract=null), Reference(id=1325221203316703801, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Pfaller M A, Sader H S, Flamm R K, et al. Oritavancin in vitro activity against Gram-positive organisms from European and United States medical centers: results from the SENTRY antimicrobial surveillance program for 2010—2014[J].Diagn Microbiol Infect Dis, 2018, 91(2): 199-204., articleTitle=null, refAbstract=null), Reference(id=1325221203392201274, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Hussein M, Barclay J, Baker M, et al. A comparative review of the pharmacology of dalbavancin and oritavancin for Gram-positive infections: birds of a feather or apples and oranges[J]. Infect Dis Ther, 2025, 14(10): 2221-2246., articleTitle=null, refAbstract=null), Reference(id=1325221203467698747, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Gavaruzzi F, Granata G, Capone A, et al. Long-term therapy with long-acting lipoglycopeptide antibiotics in the treatment of cardiovascular prosthetic infections: a systematic review[J]. Antibiotics(Basel), 2025, 14(11): 1130., articleTitle=null, refAbstract=null), Reference(id=1325221203572556348, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Mendes R E, Sader H S, Castanheira M, et al. Distribution of main Gram-positive pathogens causing bloodstream infections in United States and European hospitals during the SENTRY antimicrobial surveillance program(2010—2016):concomitant analysis of oritavancin in vitro activity[J]. J Chemother, 2018, 30(5): 280-289., articleTitle=null, refAbstract=null), Reference(id=1325221203631276605, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=van Groesen E, Innocenti P, Martin N I. Recent advances in the development of semisynthetic glycopeptide antibiotics:2014—2022[J]. ACS Infect Dis, 2022, 8(8): 1381-1407., articleTitle=null, refAbstract=null), Reference(id=1325221203698385470, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=张献, 冯欣. 万古霉素在早产儿抗感染中的应用进展[J].世界临床药物, 2022, 43(12): 1534-1540., articleTitle=null, refAbstract=null), Reference(id=1325221203752911423, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Werth B J, Zhang R T, Barreras Beltran I A, et al. Simulated exposures of oritavancin in in vitro pharmacodynamic models select for methicillin-resistant Staphylococcus aureus with reduced susceptibility to oritavancin but minimal cross-resistance or seesaw effect with other antimicrobials[J]. J Antimicrob Chemother, 2025, 80(4): 1108-1115., articleTitle=null, refAbstract=null), Reference(id=1325221203820020288, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Belley A, Lalonde seguin D, Arhin F, et al. Comparative in vitro activities of oritavancin, dalbavancin, and vancomycin against methicillin-resistant Staphylococcus aureus isolates in a nondividing state[J]. Antimicrob Agents Chemother, 2016,60(7): 4342-4345., articleTitle=null, refAbstract=null), Reference(id=1325221203882934849, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Turicchi G, Bongiovanni M. Oritavancin in a patient with recurrent endocarditis by Enterococcus faecalis: a new therapeutic option[J]. J Antimicrob Chemother, 2025,80(10): 2873-2874., articleTitle=null, refAbstract=null), Reference(id=1325221205543879234, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Yan Q, Karau M J, Patel R. In vitro activity of oritavancin against biofilms of staphylococci isolated from prosthetic joint infection[J]. Diagn Microbiol Infect Dis, 2018, 92(2):155-157., articleTitle=null, refAbstract=null), Reference(id=1325221205631959619, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Lodise T P, Redell M, Armstrong S O, et al. Efficacy and safety of oritavancin relative to vancomycin for patients with acute bacterial skin and skin structure infections(ABSSSI)in the outpatient setting: results from the SOLO clinical trials[J]. Open Forum Infect Dis, 2017, 4(1): ofw274., articleTitle=null, refAbstract=null), Reference(id=1325221205707457092, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Frondizi F, Leanza G M, Chiuchiarelli M, et al. The use of oritavancin as consolidation therapy for infective endocarditis caused by Enterococcus spp[J]. Open Forum Infect Dis,2025, 12(8): ofaf416., articleTitle=null, refAbstract=null), Reference(id=1325221205787148869, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Ciusa G, Pipitone G, Mancuso A, et al. One-shot, one opportunity: retrospective observational study on long-acting antibiotics for SSTIs in the emergency room - a real-life experience[J]. Pathogens, 2025, 14(8): 781., articleTitle=null, refAbstract=null), Reference(id=1325221205854257734, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Rubino C M, Bhavnani S M, Moeck G, et al. Population pharmacokinetic analysis for a single 1 200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials[J]. Antimicrob Agents Chemother, 2015, 59(6): 3365-3372., articleTitle=null, refAbstract=null), Reference(id=1325221205917172295, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Syed Y Y, Scott L J. Oritavancin: a review in acute bacterial skin and skin structure infections[J]. Drugs, 2015, 75(16):1891-1902., articleTitle=null, refAbstract=null), Reference(id=1325221205975892552, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Birlutiu R M, Birlutiu V. Oritavancin a therapeutic option for periprosthetic joint infections in selected cases: a comprehensive review[J]. Pharmaceuticals(Basel), 2025,18(8): 1217., articleTitle=null, refAbstract=null), Reference(id=1325221206030418505, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Krsak M, Klimpl D, Mueller S W, et al. Oritavancin for treatment of osteomyelitis: a systematic review and meta-analysis of observational studies[J]. Pharmacotherapy, 2025,45(11): 754-763., articleTitle=null, refAbstract=null), Reference(id=1325221206093333066, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Brade K D, Rybak J M, Rybak M J. Oritavancin: a new lipoglycopeptide antibiotic in the treatment of Gram-positive infections[J]. Infect Dis Ther, 2016, 5(1): 1-15., articleTitle=null, refAbstract=null), Reference(id=1325221206164636235, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Domenech O, Dufrene Y F, van Bambeke F, et al. Interactions of oritavancin, a new semi-synthetic lipoglycopeptide, with lipids extracted from Staphylococcus aureus[J]. Biochim Biophys Acta, 2010, 1798(10): 1876-1885., articleTitle=null, refAbstract=null), Reference(id=1325221206231745100, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhang H, Zhou W Y, Wang J, et al. Efficacy and safety of oritavancin for the treatment of acute bacterial skin and skin-structure infections: a systematic review and meta-analysis[J]. J Glob Antimicrob Resist, 2021, 25: 380-389., articleTitle=null, refAbstract=null), Reference(id=1325221206298853965, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Whittaker C, Lodise T P, Nhan E, et al. Expediting discharge in hospitalized, adult patients with skin and soft tissue infections who received empiric vancomycin therapy with oritavancin: description of findings from an institutional pathway[J]. Drugs Real World Outcomes, 2020, 7(Suppl 1):30-35., articleTitle=null, refAbstract=null), Reference(id=1325221206370157134, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Helton B, MacWhinnie A, Minor S B, et al. Early directed oritavancin therapy in the emergency department may lead to hospital avoidance compared to standard treatment for acute bacterial skin and skin structure infections: a real-world retrospective analysis[J]. Drugs Real World Outcomes, 2020,7(Suppl 1): 20-29., articleTitle=null, refAbstract=null), Reference(id=1325221206428877391, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=Rose W E, Hutson P R. A two-dose oritavancin regimen using pharmacokinetic estimation analysis[J]. Drugs Real World Outcomes, 2020, 7(Suppl 1): 36-40., articleTitle=null, refAbstract=null), Reference(id=1325221206525346384, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=Raza Z A, Giannini A, Bongiovanni M, et al. Oritavancin for Gram-positive bone and joint infections: a comprehensive review of the literature[J]. Antibiotics(Basel), 2026, 15(2):226., articleTitle=null, refAbstract=null), Reference(id=1325221206584066641, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=Krsak M, Morrisette T, Damioli L, et al. Can oritavancin be used for treatment and/or suppressive antimicrobial therapy of bone and joint infections caused by vancomycin-resistant Enterococcus faecium[J]. Clin Orthop Relat Res, 2025,483(7): 1225-1233., articleTitle=null, refAbstract=null), Reference(id=1325221206651175506, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=Giuliano S, Martini L, Merelli M, et al. Oritavancin as consolidation or suppressive therapy in infective endocarditis and device-related infections: real-world experience with therapeutic drug monitoring[J]. JAC Antimicrob Resist,2026, 8(4): dlag150., articleTitle=null, refAbstract=null), Reference(id=1325221206718284371, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=Miller W R, Murray B E, Rice L B, et al. Resistance in vancomycin-resistant enterococci[J]. Infect Dis Clin North Am, 2020, 34(4): 751-771., articleTitle=null, refAbstract=null), Reference(id=1325221206781198932, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=Lupia T, de Benedetto I, Bosio R, et al. Role of oritavancin in the treatment of infective endocarditis, catheter- or device-related infections, bloodstream infections, and bone and prosthetic joint infections in humans: narrative review and possible developments[J]. Life(Basel), 2023, 13(4): 959., articleTitle=null, refAbstract=null), Reference(id=1325221206852502101, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=Brownell L E, Adamsick M L, McCreary E K, et al. Clinical outcomes and economic impact of oritavancin for Gram-positive infections: a single academic medical center health system experience[J]. Drugs Real World Outcomes, 2020,7(Suppl 1): 13-19., articleTitle=null, refAbstract=null), Reference(id=1325221206919610966, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=Scoble P J, Reilly J, Tillotson G S. Real-world use of oritavancin for the treatment of osteomyelitis[J]. Drugs Real World Outcomes, 2020, 7(Suppl 1): 46-54., articleTitle=null, refAbstract=null), Reference(id=1325221207007691351, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=Bradley J, Arrieta A, Bokesch P, et al. 1719.Pharmacokinetics(PK) of oritavancin in children: the ORKIDS trial[J]. Open Forum Infect Dis, 2018, 5(Suppl 1):S52., articleTitle=null, refAbstract=null), Reference(id=1325221207095771736, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=叶静, 肖婷婷, 王雪婷, 等. 新型抗菌药物研究进展与临床应用[J]. 药学进展, 2021, 45(6): 403-412., articleTitle=null, refAbstract=null), Reference(id=1325221207188046425, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=Mitra S, Saeed U, Havlichek D H, et al. Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infections[J]. Infect Drug Resist, 2015, 8: 189-197., articleTitle=null, refAbstract=null), Reference(id=1325221207276126810, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=Shaju A M, Panicker N, Chandni V, et al. Drugs-associated with red man syndrome: an integrative approach using disproportionality analysis and Pharmip[J]. J Clin Pharm Ther, 2022, 47(10): 1650-1658., articleTitle=null, refAbstract=null)], funds=[Fund(id=1325221202846941748, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, awardId=23YF1445700, language=CN, fundingSource=上海市2023年度“科技创新行动计划”启明星项目(扬帆专项)(23YF1445700), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1325221197658587666, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, xref=null, ext=[AuthorCompanyExt(id=1325221197683753491, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, companyId=1325221197658587666, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1325221197704725012, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, companyId=1325221197658587666, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海 201203)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2026.08.017, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2026.08.017, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2026.08.017, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2026.08.017, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1786291200000, fullTextJson=null, articleText=null, reference=null)
收藏切换
抗感染药物奥利万星的临床研究进展
卢强 , 汤文 , 李会 , 奕栋 , 谭俊 *
世界临床药物 | 综述评论 2026,47(8): 946-950
收起
收藏切换
世界临床药物 |综述评论 2026 , 47 (8) : 946 -950
抗感染药物奥利万星的临床研究进展
全屏
[Author(id=1325221198086406678, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1325221198182875672, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, authorId=1325221198086406678, language=EN, stringName=Qiang LU, firstName=Qiang, middleName=null, lastName=LU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=China State Institute of Pharmaceutical Industry, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1325221198568751641, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, authorId=1325221198086406678, language=CN, stringName=卢强, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院,上海 201203, bio={"content":"

卢强,硕士研究生,研究方向:微生物药物。

"}, bioImg=null, bioContent=

卢强,硕士研究生,研究方向:微生物药物。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1325221197658587666, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, xref=null, ext=[AuthorCompanyExt(id=1325221197683753491, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, companyId=1325221197658587666, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1325221197704725012, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, companyId=1325221197658587666, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海 201203)])]), Author(id=1325221198925267483, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1325221199034319389, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, authorId=1325221198925267483, language=EN, stringName=Wen TANG, firstName=Wen, middleName=null, lastName=TANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=China State Institute of Pharmaceutical Industry, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1325221199340503582, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, authorId=1325221198925267483, language=CN, stringName=汤文, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1325221197658587666, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, xref=null, ext=[AuthorCompanyExt(id=1325221197683753491, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, companyId=1325221197658587666, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1325221197704725012, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, companyId=1325221197658587666, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海 201203)])]), Author(id=1325221199407612448, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1325221201076945442, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, authorId=1325221199407612448, language=EN, stringName=Hui LI, firstName=Hui, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=China State Institute of Pharmaceutical Industry, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1325221201160831523, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, authorId=1325221199407612448, language=CN, stringName=李会, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1325221197658587666, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, xref=null, ext=[AuthorCompanyExt(id=1325221197683753491, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, companyId=1325221197658587666, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1325221197704725012, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, companyId=1325221197658587666, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海 201203)])]), Author(id=1325221201215357477, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1325221201521541671, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, authorId=1325221201215357477, language=EN, stringName=Dong YI, firstName=Dong, middleName=null, lastName=YI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=China State Institute of Pharmaceutical Industry, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1325221201588650536, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, authorId=1325221201215357477, language=CN, stringName=奕栋, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1325221197658587666, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, xref=null, ext=[AuthorCompanyExt(id=1325221197683753491, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, companyId=1325221197658587666, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1325221197704725012, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, companyId=1325221197658587666, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海 201203)])]), Author(id=1325221201848697386, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1325221201928389164, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, authorId=1325221201848697386, language=EN, stringName=Jun TAN, firstName=Jun, middleName=null, lastName=TAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=China State Institute of Pharmaceutical Industry, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1325221202003886637, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, authorId=1325221201848697386, language=CN, stringName=谭俊, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=中国医药工业研究总院,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1325221197658587666, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, xref=null, ext=[AuthorCompanyExt(id=1325221197683753491, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, companyId=1325221197658587666, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1325221197704725012, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325221194428973581, companyId=1325221197658587666, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海 201203)])])]
卢强, 汤文, 李会, 奕栋, 谭俊*
作者信息
  • 中国医药工业研究总院,上海 201203
通讯作者:
谭俊,副研究员,研究方向:微生物药物。
作者简介:

卢强,硕士研究生,研究方向:微生物药物。

Clinical research progress of the anti-infective drug oritavancin
Qiang LU, Wen TANG, Hui LI, Dong YI, Jun TAN*
Affiliations
  • China State Institute of Pharmaceutical Industry, Shanghai 201203, China
出版时间: 2026-08-10 doi: 10.13683/j.wph.2026.08.017
文章导航
收藏切换

奥利万星是一种新型糖肽类抗菌药物,对多重耐药菌具有广谱抗菌活性,特别对耐甲氧西林金黄色葡萄球菌和万古霉素耐药菌株具有极佳的抗菌活性。奥利万星主要用于治疗革兰氏阳性菌引起的急性细菌性皮肤及皮肤结构感染,具有给药便携性优势。该文主要对奥利万星的临床研究作综述,以期为其临床应用提供参考。

奥利万星  /  耐甲氧西林金黄色葡萄球菌  /  急性细菌性皮肤及皮肤结构感染

Oritavancin is a novel antimicrobial agents with broad-spectrum antibacterial activity against multi-drug resistant bacteria, particularly showing excellent activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant strains. Oritavancin is mainly used to treat acute bacterial skin and skin structure infections caused by Gram-positive bacteria and offers the advantage of convenient administration. This article mainly reviewed the clinical studies and related aspects of oritavancin, in order to provide reference for its clinical application.

oritavancin  /  methicillin-resistant Staphylococcus aureus  /  acute bacterial skin and skin structure infections
卢强, 汤文, 李会, 奕栋, 谭俊. 抗感染药物奥利万星的临床研究进展. 世界临床药物, 2026 , 47 (8) : 946 -950 . DOI: 10.13683/j.wph.2026.08.017
Qiang LU, Wen TANG, Hui LI, Dong YI, Jun TAN. Clinical research progress of the anti-infective drug oritavancin[J]. World Clinical Drug, 2026 , 47 (8) : 946 -950 . DOI: 10.13683/j.wph.2026.08.017
  • 上海市2023年度“科技创新行动计划”启明星项目(扬帆专项)(23YF1445700)
参考文献 引证文献
排序方式:
[1]
Turner N A, Sharma-Kuinkel B K, Maskarinec S A, et al.Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research[J]. Nat Rev Microbiol, 2019,17(4): 203-218.
[2]
Galfo V, Tiseo G, Riccardi N, et al. Therapeutic drug monitoring of antibiotics for methicillin-resistant Staphylococcus aureus infections: an updated narrative review for clinicians[J]. Clin Microbiol Infect, 2025, 31(2):194-200.
[3]
刘珊, 樊钱永. 沈舜义. 抗生素临床研究新进展[J]. 世界临床药物, 2017, 38(3): 200-203.
[4]
Jean S S, Liu I M, Hsieh P C, et al. Off-label use versus formal recommendations of conventional and novel antibiotics for the treatment of infections caused by multidrug-resistant bacteria[J]. Int J Antimicrob Agents, 2023, 61(5): 106763.
[5]
Pfaller M A, Sader H S, Flamm R K, et al. Oritavancin in vitro activity against Gram-positive organisms from European and United States medical centers: results from the SENTRY antimicrobial surveillance program for 2010—2014[J].Diagn Microbiol Infect Dis, 2018, 91(2): 199-204.
[6]
Hussein M, Barclay J, Baker M, et al. A comparative review of the pharmacology of dalbavancin and oritavancin for Gram-positive infections: birds of a feather or apples and oranges[J]. Infect Dis Ther, 2025, 14(10): 2221-2246.
[7]
Gavaruzzi F, Granata G, Capone A, et al. Long-term therapy with long-acting lipoglycopeptide antibiotics in the treatment of cardiovascular prosthetic infections: a systematic review[J]. Antibiotics(Basel), 2025, 14(11): 1130.
[8]
Mendes R E, Sader H S, Castanheira M, et al. Distribution of main Gram-positive pathogens causing bloodstream infections in United States and European hospitals during the SENTRY antimicrobial surveillance program(2010—2016):concomitant analysis of oritavancin in vitro activity[J]. J Chemother, 2018, 30(5): 280-289.
[9]
van Groesen E, Innocenti P, Martin N I. Recent advances in the development of semisynthetic glycopeptide antibiotics:2014—2022[J]. ACS Infect Dis, 2022, 8(8): 1381-1407.
[10]
张献, 冯欣. 万古霉素在早产儿抗感染中的应用进展[J].世界临床药物, 2022, 43(12): 1534-1540.
[11]
Werth B J, Zhang R T, Barreras Beltran I A, et al. Simulated exposures of oritavancin in in vitro pharmacodynamic models select for methicillin-resistant Staphylococcus aureus with reduced susceptibility to oritavancin but minimal cross-resistance or seesaw effect with other antimicrobials[J]. J Antimicrob Chemother, 2025, 80(4): 1108-1115.
[12]
Belley A, Lalonde seguin D, Arhin F, et al. Comparative in vitro activities of oritavancin, dalbavancin, and vancomycin against methicillin-resistant Staphylococcus aureus isolates in a nondividing state[J]. Antimicrob Agents Chemother, 2016,60(7): 4342-4345.
[13]
Turicchi G, Bongiovanni M. Oritavancin in a patient with recurrent endocarditis by Enterococcus faecalis: a new therapeutic option[J]. J Antimicrob Chemother, 2025,80(10): 2873-2874.
[14]
Yan Q, Karau M J, Patel R. In vitro activity of oritavancin against biofilms of staphylococci isolated from prosthetic joint infection[J]. Diagn Microbiol Infect Dis, 2018, 92(2):155-157.
[15]
Lodise T P, Redell M, Armstrong S O, et al. Efficacy and safety of oritavancin relative to vancomycin for patients with acute bacterial skin and skin structure infections(ABSSSI)in the outpatient setting: results from the SOLO clinical trials[J]. Open Forum Infect Dis, 2017, 4(1): ofw274.
[16]
Frondizi F, Leanza G M, Chiuchiarelli M, et al. The use of oritavancin as consolidation therapy for infective endocarditis caused by Enterococcus spp[J]. Open Forum Infect Dis,2025, 12(8): ofaf416.
[17]
Ciusa G, Pipitone G, Mancuso A, et al. One-shot, one opportunity: retrospective observational study on long-acting antibiotics for SSTIs in the emergency room - a real-life experience[J]. Pathogens, 2025, 14(8): 781.
[18]
Rubino C M, Bhavnani S M, Moeck G, et al. Population pharmacokinetic analysis for a single 1 200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials[J]. Antimicrob Agents Chemother, 2015, 59(6): 3365-3372.
[19]
Syed Y Y, Scott L J. Oritavancin: a review in acute bacterial skin and skin structure infections[J]. Drugs, 2015, 75(16):1891-1902.
[20]
Birlutiu R M, Birlutiu V. Oritavancin a therapeutic option for periprosthetic joint infections in selected cases: a comprehensive review[J]. Pharmaceuticals(Basel), 2025,18(8): 1217.
[21]
Krsak M, Klimpl D, Mueller S W, et al. Oritavancin for treatment of osteomyelitis: a systematic review and meta-analysis of observational studies[J]. Pharmacotherapy, 2025,45(11): 754-763.
[22]
Brade K D, Rybak J M, Rybak M J. Oritavancin: a new lipoglycopeptide antibiotic in the treatment of Gram-positive infections[J]. Infect Dis Ther, 2016, 5(1): 1-15.
[23]
Domenech O, Dufrene Y F, van Bambeke F, et al. Interactions of oritavancin, a new semi-synthetic lipoglycopeptide, with lipids extracted from Staphylococcus aureus[J]. Biochim Biophys Acta, 2010, 1798(10): 1876-1885.
[24]
Zhang H, Zhou W Y, Wang J, et al. Efficacy and safety of oritavancin for the treatment of acute bacterial skin and skin-structure infections: a systematic review and meta-analysis[J]. J Glob Antimicrob Resist, 2021, 25: 380-389.
[25]
Whittaker C, Lodise T P, Nhan E, et al. Expediting discharge in hospitalized, adult patients with skin and soft tissue infections who received empiric vancomycin therapy with oritavancin: description of findings from an institutional pathway[J]. Drugs Real World Outcomes, 2020, 7(Suppl 1):30-35.
[26]
Helton B, MacWhinnie A, Minor S B, et al. Early directed oritavancin therapy in the emergency department may lead to hospital avoidance compared to standard treatment for acute bacterial skin and skin structure infections: a real-world retrospective analysis[J]. Drugs Real World Outcomes, 2020,7(Suppl 1): 20-29.
[27]
Rose W E, Hutson P R. A two-dose oritavancin regimen using pharmacokinetic estimation analysis[J]. Drugs Real World Outcomes, 2020, 7(Suppl 1): 36-40.
[28]
Raza Z A, Giannini A, Bongiovanni M, et al. Oritavancin for Gram-positive bone and joint infections: a comprehensive review of the literature[J]. Antibiotics(Basel), 2026, 15(2):226.
[29]
Krsak M, Morrisette T, Damioli L, et al. Can oritavancin be used for treatment and/or suppressive antimicrobial therapy of bone and joint infections caused by vancomycin-resistant Enterococcus faecium[J]. Clin Orthop Relat Res, 2025,483(7): 1225-1233.
[30]
Giuliano S, Martini L, Merelli M, et al. Oritavancin as consolidation or suppressive therapy in infective endocarditis and device-related infections: real-world experience with therapeutic drug monitoring[J]. JAC Antimicrob Resist,2026, 8(4): dlag150.
[31]
Miller W R, Murray B E, Rice L B, et al. Resistance in vancomycin-resistant enterococci[J]. Infect Dis Clin North Am, 2020, 34(4): 751-771.
[32]
Lupia T, de Benedetto I, Bosio R, et al. Role of oritavancin in the treatment of infective endocarditis, catheter- or device-related infections, bloodstream infections, and bone and prosthetic joint infections in humans: narrative review and possible developments[J]. Life(Basel), 2023, 13(4): 959.
[33]
Brownell L E, Adamsick M L, McCreary E K, et al. Clinical outcomes and economic impact of oritavancin for Gram-positive infections: a single academic medical center health system experience[J]. Drugs Real World Outcomes, 2020,7(Suppl 1): 13-19.
[34]
Scoble P J, Reilly J, Tillotson G S. Real-world use of oritavancin for the treatment of osteomyelitis[J]. Drugs Real World Outcomes, 2020, 7(Suppl 1): 46-54.
[35]
Bradley J, Arrieta A, Bokesch P, et al. 1719.Pharmacokinetics(PK) of oritavancin in children: the ORKIDS trial[J]. Open Forum Infect Dis, 2018, 5(Suppl 1):S52.
[36]
叶静, 肖婷婷, 王雪婷, 等. 新型抗菌药物研究进展与临床应用[J]. 药学进展, 2021, 45(6): 403-412.
[37]
Mitra S, Saeed U, Havlichek D H, et al. Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infections[J]. Infect Drug Resist, 2015, 8: 189-197.
[38]
Shaju A M, Panicker N, Chandni V, et al. Drugs-associated with red man syndrome: an integrative approach using disproportionality analysis and Pharmip[J]. J Clin Pharm Ther, 2022, 47(10): 1650-1658.
2026年第47卷第8期
70
16
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2026.08.017
  • 接收时间:2026-03-11
  • 首发时间:2026-11-05
  • 出版时间:2026-08-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2026-03-11
基金
上海市2023年度“科技创新行动计划”启明星项目(扬帆专项)(23YF1445700)
作者信息
    中国医药工业研究总院,上海 201203

通讯作者:

谭俊,副研究员,研究方向:微生物药物。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2026.08.017
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏